27 Optimal methods for the diagnosis of rectal gonococcal and chlamydial infection are uncertain. 28 This study evaluated performance of culture and nucleic acid amplification tests (NAATs) for 29 rectal chlamydial and gonococcal diagnosis. From July 2003 until February 2007, 441 rectal test 30 sets were collected from individuals attending a sexually transmitted disease clinic and 3 HIV 31 clinics who gave a history of anal intercourse or were women at high risk for N. gonorrhoeae or 32 C. trachomatis infections. Rectal swab specimens were tested using culture and commercial 33 NAATs employing Transcription Mediated Amplification (TMA), Strand Displacement 34 Amplification (SDA), and Polymerase Chain Reaction (PCR) Amplification. Test performance 35 was evaluated using a rotating standard by which patients were classified infected if either two or 36 three comparator tests were positive. Test sensitivities for the detection of N. gonorrhoeae 37 ranged from 66.7% to 71.9% for culture to 100% for TMA. Specificities were 99.7% to 100% 38 for culture and greater than 95.5% for all 3 NAATs. Test sensitivities for C. trachomatis ranged 39 from 36.1% to 45.7% for culture and among NAATS from 91.4% to 95.8% for PCR to 100% for 40 TMA. Specificities of the NAATs ranged from 95.6% to 98.5% (2 of 3 standard) and from 41 88.8% to 91.8% (3 of 3 standard). Over 60% and 80% of gonococcal and chlamydial infections 42 among men who have sex with men and over 20% of chlamydial infections in women, 43 respectively, would have been missed if the rectal site had not been tested. Currently available 44 NAATs are more sensitive than culture for detection of chlamydial and gonococcal infection at 45 the rectal site. 46 47
Historically, the focus of sexually transmitted diseases (STD) diagnostic testing has been on 53 development and evaluation of tests for diagnosis of genital infections. However, a substantial 54 proportion of the population engages in non-genital (e.g. oral or anal) sexual activity. For 55 instance, a recent study conducted at 3 U.S. STD clinics found that 37% of heterosexual clients 56 reported ever practicing anal intercourse and over a quarter (28.9%) reported this activity with at 57 least one of their last 3 sexual partners (4). These clinic-based findings are consistent with 58 results of population-based studies indicating that 30%-40% of U.S. men and women had ever 59 engaged in anal sex with an opposite sex partner (11, 13) . In addition, among men-who-have-60 sex-with-men (MSM), there is evidence that non-genital sites may serve as, often asymptomatic, 61 reservoirs of gonococcal and chlamydial infection with one study demonstrating infection rates 62 of 7% for gonorrhea and 8% for chlamydia; among men with urethral, pharyngeal, and rectal 63 exposures, 54% of chlamydial infections and 21% of gonococcal infections involved only the 64 rectum (10). In an earlier study utilizing chlamydia culture techniques, Jones and colleagues 65 found that 6.4% (24 of 373) of women with chlamydial infection harbored the organism at the 66 rectal site only and therefore would have been missed in the absence of rectal chlamydia testing 67 (9) . 68 69 In recent years, culture testing for genital STDs has been largely supplanted by use of non-70 culture tests, yet no non-culture tests are currently approved for use at the rectal site. In addition, 71 as outlined above, increased appreciation of the potential import of non-genital STDs has 72 contributed to the need for sensitive and specific tests to diagnose rectal gonococcal and 73 chlamydial infections. Nucleic acid amplification tests (NAATs) have been found to be more 74 sensitive than culture for detection of genital gonococcal and chlamydial infections but there are 75 limited comparative data on the performance of commercially available NAATs for diagnosis of 76 extra-genital STDs. To help address these deficits, we conducted a study to compare the 77 performance of culture and NAATS commercially available in the U.S. Although these tests are 78 not cleared by the U.S. Food and Drug Administration (FDA) for oral or rectal C. trachomatis 79 and N. gonorrhoeae diagnosis, some clinical laboratories are utilizing these tests on rectal 80 specimens after performing the limited in-house verification study required by the Clinical 81 Laboratory Improvement Act (1). To help address deficits in critical evaluation of the 82 performance of NAATs for diagnosis of extragenital gonococcal and chlamydial infection, we 83 conducted a study comparing the performance of culture and NAATs commercially available in 84 the U.S. The results for diagnosis of oral infections have been reported (2); this paper describes 85 the results with respect to diagnosis of rectal gonorrhea and chlamydial infection. At each site participants were eligible for enrollment if they were over age 15, had engaged in 94 receptive anal sex within the preceding 2 months and were willing and able to sign written 95 informed consent. Due to high rates of concurrent rectal infection in women with cervical 96 gonoccocal and chlamydial infections (15,17), female participants were also eligible for 97 enrollment in the absence of a history of anal sex if they presented to clinic as a contact to sexual 98 partners with N. gonorrhoeae, C. trachomatis or nongonococcal urethritis (NGU) or if they 99 presented for treatment for a previously collected but untreated positive gonorrhea or chlamydia 100 test. Participants were ineligible if they had received antibiotics active against N. gonorrhoeae 101 and/or C. trachomatis within 30 days of study enrollment. 102
Following written informed consent, each participant answered a brief survey followed by the 104 collection of four rectal swabs. Each rectal swab was inserted approximately 5 cm into the 105 rectum, and rotated against the rectal wall several times. Swabs grossly contaminated with feces 106 were discarded and collection repeated. Swabs used for specimen collection included the 107 following: a cotton-tipped swab for inoculation onto gonorrhea culture media, a Dacron swab for 108 chlamydia culture and PCR (Roche COBAS) and specimen collection swabs contained in the 109 test kits for Gen-Probe APTIMA Combo 2® and BDProbeTec™ ET Amplified DNA assays, 110 respectively. Following collection, specimens were stored according to manufacturers' 111 instructions and were transported to the University of Alabama at Birmingham STD Research 112
Laboratory daily for testing. Swab order was rotated at 3 month intervals throughout the study 113 period. NAAT-based test was utilized. Patients with one or more positive tests and who had not 123 received appropriate therapy on the day of enrollment, were asked to allow the study staff to 124 recollect all four swabs at the time that they presented for treatment, though the recollected test 125 sets were not included in the current analysis. All study procedures were approved by the 126 (Table 2b) . 234
235
We calculated prevalences of N. gonorrhoeae and C. trachomatis based on a composite test 236 measure with infection defined as a positive culture and/or two or more positive NAATs. 237
Among men, all of whom reported rectal exposure, the prevalence of rectal N. gonorrhoeae 238 infection was 7.9% (95%CI 5.0-11.7%) based on the composite standard and the prevalence of 239 C. trachomatis infection was 10.3% (95%CI 7.1-14.4%) ( Table 3) . Prevalence of N. 240 gonorrhoeae in females ranged from 5.6% (95% CI 0.7-18.7%) in women with rectal exposure 241 to 19.2% (95%CI 6.6-39.4%) in women reporting contact to an STD. C. trachomatis prevalence 242 in women was 23.1% (95%CI 11.1-39.3%) in women engaging in rectal sex and over 50% in 243 women presenting for treatment for a previously diagnosed STD (Table 3) . NAATs are substantially more sensitive than culture. Based on the standard of 2 of 3 261 comparator tests positive, sensitivity for gonorrhea detection was only 66.7% for gonococcal 262 culture, but ranged from 91.4% to 100% for the NAATs. Utilizing the 3 out of 3 comparator 263 tests positive as the standard, sensitivity was 71.9% for culture, but sensitivities ranged from 264 95.8% to 100% for the NAATs. The differences between test performance for chlamydia 265 diagnosis were even more marked, in large part due to the low sensitivity of chlamydial culture. 266
The low sensitivity of chlamydial culture found in this study (ranging from 36.1% to 45.7%) is 267 consistent with the low chlamydial rectal culture sensitivities noted by Schachter and colleagues 268 (26.5%-39.1%, depending on the standard utilized) (14). These findings are also consistent with 269 the superior sensitivity of NAATs documented at the genital site and support findings from 270
Schachter and colleagues who recently reported similar data using different methodology (14). 271
They withdrew PCR early in their study due to a high oral false-positive rate for N. gonorrhoeae 272 for oral specimens. The rectal specimen sensitivity estimates for PCR (44.4%) and SDA 273 (77.8%) in their truncated sample (18 infected subjects) were lower than our estimates, which 274 exceeded 91% for both tests. Much of the difference for SDA may have been due to their 275 truncated sample size, since the final SDA sensitivity result for their full sample was 88.5% (78 276 infected subjects) when they used a gold standard that incorporated the evaluated tests, but did 277 not perform discrepant analysis (14). The truncated sample size for PCR and differences in gold 278 standard probably account for some of the differences between our study and theirs in sensitivity 279 estimates for PCR as well. While the specificity of PCR, SDA, and TMA in this study are 280 slightly lower than the specificity of culture, they are still within an acceptable range for many 281 clinical situations. 282
The specificities of PCR, SDA, and TMA that we obtained were lower than the specificities 284 reported by Schachter and colleagues(14) . These differences demonstrate the analytic challenges 285 associated with the definition of "infection" in the absence of an agreed upon gold standard and 286 their impact on estimates of test sensitivity or specificity. Using any two positive of three 287 comparator tests to define infection, culture detected only 66.7% and 36.1% of gonococcal and 288 chlamydial infections, respectively, while when we applied the more rigorous standard requiring 289 all three comparators to agree, the sensitivity of culture increased, but only to 71.9% (for 290 gonorrhea) and 45.7% (for chlamydia). Estimated sensitivities for the NAATs also increased. 291 At the same time, a consequence of using the more stringent definition of infection was a decline 292 in estimated specificities. Had we chosen the least stringent definition of sensitivity, requiring 293 only one of the three comparator tests to define infection, the estimated sensitivities of culture 294 and the NAATs would have been still lower while the estimated specificities would have been 295 both higher and more stringently defined. Using the rotating standard for defining infection 296 introduced similar biases to each estimate of sensitivity and specificity for each of the assays 297 evaluated in our study. The higher specificity estimates obtained by Schachter and 298 colleagues(14) resulted at least in part from their use of gold standards that incorporated the 299 result of the evaluated test. Disagreement exists regarding the extent of the associated positive 300 bias(5,7). In the absence of an agreed upon gold standard, it seems reasonable to presume that 301 the true specificity of the NAATs falls between the estimates in this study and the Schachter and 302 colleagues study(14), which is acceptable for screening and diagnostic testing of at-risk 303 individuals. Importantly, in contrast to the case with pharyngeal specimens, neither study 304 demonstrated the reduced specificity of Roche COBAS AMPLICOR™ PCR to detect N. 305 gonorrhoeae in rectal specimens that had been observed previously with pharyngeal 306 specimens(2,14). Presumably this difference can be attributed to the common occurrence of This study reinforces previous reports describing the high prevalence of rectal infection among 312 MSM with rectal exposure, especially when tested by a NAAT (Table 3) (1,6,10). Moreover, as 313 has been found in earlier studies (10), patients were not concordant for infection at all sites 314 (Tables 4a and 4b ). Over 60% of gonococcal infections and over 80% of chlamydial infections 315 diagnosed in MSM study participants that had tests performed at both genital and rectal sites had 316 positive rectal results only and would have been missed if the rectal site had not been tested. 317
This study also leads to insights related to gonococcal and chlamydial prevalence among 318 heterosexual women. The prevalence of rectal gonococcal infection was similar between male 319 and female participants reporting rectal intercourse while women enrolled because of a contact to 320 an STD or with an untreated STD had the highest prevalence of rectal gonorrhea, a finding that 321 may have been impacted by the fact that 7 (25.9%) women reporting contact to STD and 2 322 (7.4%) women presenting with untreated chlamydial infection also reported rectal sexual activity 323 and therefore there was some overlap in the indications for enrollment in the study (data not 324 shown). The proportion of women infected with chlamydia at the rectal site was roughly 2 to 325 over 5 times higher than men, depending on enrollment group (Table 3) 447  448  449  450  451  452  453  454  455  456  457  458  459  460  461  462  463  464  465  466  467  468  469  470  471  472  473  474  475  476  477  478 on October 3, 2017 by guest http://jcm.asm.org/ Downloaded from 
